{"id":"ptx-022","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5893587","moleculeType":null,"molecularWeight":"423.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PTX-022 targets PI3K signaling, which plays a critical role in immune cell activation, proliferation, and survival. By selectively inhibiting PI3K, the drug aims to enhance anti-tumor immune responses while potentially reducing immunosuppressive signals in the tumor microenvironment. This mechanism is intended to improve outcomes in cancer immunotherapy.","oneSentence":"PTX-022 is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) designed to modulate immune cell function and tumor microenvironment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:40.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06653842","phase":"PHASE2","title":"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-12-20","conditions":"Cutaneous Venous Malformations","enrollment":15},{"nctId":"NCT05050149","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2022-01-13","conditions":"Microcystic Lymphatic Malformation","enrollment":12},{"nctId":"NCT03920228","phase":"PHASE2, PHASE3","title":"Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2019-04-01","conditions":"Pachyonychia Congenita","enrollment":73},{"nctId":"NCT04520750","phase":"PHASE3","title":"VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2020-09-01","conditions":"Pachyonychia Congenita","enrollment":36},{"nctId":"NCT04893486","phase":"PHASE2","title":"CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2021-05-06","conditions":"BCCs in Gorlin Syndrome Patients","enrollment":73},{"nctId":"NCT05643872","phase":"PHASE3","title":"A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita","status":"RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2022-11-15","conditions":"Pachyonychia Congenita","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PTX-022","genericName":"PTX-022","companyName":"Palvella Therapeutics, Inc.","companyId":"palvella-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PTX-022 is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) designed to modulate immune cell function and tumor microenvironment. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}